IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions

This publication has 33 references indexed in Scilit:

• Marketing approval of mogamulizumab
  mAbs, 2012
• Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells
  Haematologica, 2012
• Neutrophils in the activation and regulation of innate and adaptive immunity
  Nature Reviews Immunology, 2011
• Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
  Proceedings of the National Academy of Sciences, 2011
• Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors
  Medicinal Research Reviews, 2011
• Trastuzumab-Induced HER Reprogramming in “Resistant” Breast Carcinoma Cells
  Cancer Research, 2009
• The function of immunoglobulin A in immunity
  The Journal of Pathology, 2005
• Insights into IgA-mediated immune responses from the crystal structures of human FcαRI and its complex with IgA1-Fc
  Nature, 2003
• Evaluation of HER-2/neu Immunohistochemical Assay Sensitivity and Scoring on Formalin-Fixed and Paraffin-Processed Cell Lines and Breast Tumors
  American Journal of Clinical Pathology, 2002
• Hybrid IgA2/IgG1 Antibodies with Tailor-Made Effector Functions
  Clinical Immunology, 2001